January 29, 2003

FOR: ZOLL Medical Corporation

Chief Financial Officer
ZOLL Medical Corporation
(978) 421-9655
PRESS CONTACT: Robert Minicucci
Corporate Communications Manager
ZOLL Medical Corporation
+1 (978) 421-9832


ZOLL Medical Corporation Continues To Build Momentum in the Military Market

Wednesday, January 29, 2003 – ZOLL Medical Corporation (NASDAQ: ZOLL), a manufacturer of non-invasive cardiac resuscitation devices, today announced that it has won another major piece of business to supply its products to military customers. The United Kingdom Ministry of Defense has chosen the ZOLL M Series to upgrade its defibrillation technology for its Armed Forces. The deal involved 60 M Series devices and called for immediate delivery of the product.

Additionally, the company announced that it has received an order from the U.S. Navy Logistics Committee for the purchase of 65 M Series CCT biphasic transport defibrillators. This award is a follow-on to the previously announced Patient Movement Item (PMI) program contract award. The total amount of this additional award is slightly more than $ 1 million.

Richard A. Packer, President and Chief Executive Officer of ZOLL stated, “We believe the M Series is clearly becoming the product of choice for military customers around the globe. The harsh environment in which the military customer uses a defibrillator provides a unique challenge. The M Series’ ruggedness, small size and weight, and ease of use make it ideal for the military environment.”

ZOLL has been the exclusive supplier to the German Army since 1999, supplying well over 1500 units to this customer since the award of the contract. In addition, the company most recently supplied M Series to military customers in China, Israel and Poland. Previously, M Series were purchased by the Military Police in Brazil and the Secretary of Defense in Mexico. Other military customers include those in Spain and South Africa.

Mr. Packer concluded, “We are excited to be receiving awards from many military organizations around the globe. These awards reflect the increased visibility that ZOLL has gained in the International arena as we continue to expand our worldwide selling efforts, as well as the strength of the M Series product line. We hope to continue this momentum and further standardize additional military customers to the M Series, and our new AED Plus product lines.”

ZOLL Medical Corporation, headquartered in Burlington, MA, designs, manufactures and markets an integrated line of proprietary, non-invasive resuscitation devices and disposable electrodes. Used by health care professionals to provide both types of cardiac resuscitation—pacing and defibrillation—these products are essential in the emergency treatment of cardiac arrest victims, both inside and outside the hospital. ZOLL also designs and markets software that automates collection and management of both clinical and non-clinical data for emergency medical service providers. ZOLL has operations in the United States, Canada, United Kingdom, Germany, France, the Netherlands and Australia, and business partners in all of the world’s major markets. For more information about ZOLL and its products, visit www.zoll.com.

Certain statements contained in this press release, including statements regarding the anticipated development of ZOLL’s business, the intent, belief or current expectations of ZOLL, its directors or its officers, primarily with respect to ZOLL’s business model and future operating performance of ZOLL, including expectations regarding results in future periods, operating performance and contributions to results from ZOLL’s new Public Access Defibrillation product, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the ZOLL’s Annual Report on Form 10-K filed on December 30, 2002, including the future performance of the direct sales operations, as well as uncertainties regarding the market, acceptance and profitability of the ZOLL AED Plus and M Series CCT, the length and severity of the current economic slowdown and its impact on capital spending budgets, the reduction in overall capital equipment expenditures in the hospital and pre-hospital markets, the impact of governmental budget restraints on the purchase of capital equipment, the impact of the continued war on terrorism, the potential disruption in the transportation industry on ZOLL’s supply chain and product distribution channels, and the desire or ability of other parties to purchase ZOLL’s products.

# # #